| News

Alentis secures 67 million US dollars

18.06.2021

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds will be deployed to develop its pipeline of drugs treating advanced liver and kidney fibrosis.

Thomas Baumert, Founder and Executive BoD

Alentis Therapeutics develops anti-fibrotic molecules to treat advanced liver and kidney fibrosis and also, by means of its proprietary platform, works on programs targeting other fibrotic diseases and hepatobiliary cancers.

Now, the Basel-based biotechnology company has secured 67 million US dollars in a series B funding round according to a press release. This will be used to bring Alentis’s lead product, monoclonal antibodies targeting claudin-1through a proof-of-concept study. Professor Thomas Baumert of the University of Strasbourg, who founded Alentis, is quoted in the press release, saying: “Fibrosis is an important risk factor for cancer, and Claudin-1 has a well-established role in cancer biology including tumor invasion and metastasis. Given the absent and unsatisfactory treatment options, it’s critical that we deliver new therapeutics for patients suffering from fibrosis and cancer.”

BaseLaunch, the biotech incubator and accelerator of Basel Area Business & Innovation, provided Alentis with decisive support during its founding phase and helped setting up the company in Basel. The funding round was led by Morningside Venture Investments and joined by Jeito Capital as well as the the Series A investors.

Jason Dinges from Morningside and Rafaèle Tordjman, Founder and CEO of Jeito Capital, have been welcomed to the Board of Directors. “Alentis has an outstanding and experienced team from pharma and biotech and is focused on a unique target, based on the founder’s work and his team of more than 10 years,” Tordjman is quoted as saying in the press release. Alentis Therapeutics plans to start the first clinical trials in Q4 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Ontotext opens new office in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Ontotext opens new office in the Basel Area

Ontotext, a company based in New York City and the Bulgarian capital of Sofia, has opened a new location at...

Read More
Owkin heads to Basel
Basel Area Business & Innovation, Innovation, Invest

Owkin heads to Basel

The Franco-US startup Owkin is establishing a branch office in Basel. The company develops solutions for the life sciences industry...

Read More
Danish AI company settling in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Danish AI company settling in the Basel Area

Abzu has settled on the Novartis Campus of the Switzerland Innovation Park Basel Area. From there, the Danish deep tech...

Read More
«I always wanted to create something from scratch»
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

«I always wanted to create something from scratch»

Already when he was young, he was driven to create and invent. Today at the age of 33, Gwenael Hannema...

Read More
The i4Challenge announces the winners of 2021
Basel Area Business & Innovation, Innovation

The i4Challenge announces the winners of 2021

The i4Challenge shines a light on companies and innovators who help to facilitate the industrial transformation. We present the winners...

Read More
Basel Area becomes the Swiss hotspot for Chinese pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area becomes the Swiss hotspot for Chinese pharma companies

More and more Chinese pharmaceutical companies are choosing the Basel Area as location for their subsidiary in Switzerland. Among them...

Read More
1 2 3 18

Do you have a question? We'd like to hear from you.